Progressive Supranuclear Palsy Clinical Trial
Official title:
tDCS Plus Physical Therapy for Progressive Supranuclear Palsy: a Double Blind Randomized Sham-controlled Study With Wearing Sensors Technology
Objective of the study:
To test the efficacy of cerebellar transcranial direct current stimulation (tDCS) associated
with physical rehabilitation on postural instability and falls in progressive supranuclear
palsy using a double-blind design and wearing sensors technology
Design:
Twenty probable PSP patients with no dementia and still able to walk will be recruited for a
randomized double-blind sham-controlled study. Each patient will be hospitalized for a four
week physical rehabilitation. In the real-arm, the patients will undergo a ten cerebellar
tDCS stimulations while the placebo arm will undergo sham stimulation.
Each patient will be evaluated before and after stimulation by PSP-rating scale (PSP-RS),
cognitive tests and a battery of gait and movement tests using wearing sensors technology.
Background:
There are no medical effective treatments for progressive supranuclear palsy (PSP). Imaging,
neurophysiology and pathology studies suggested cerebellum as possible target of brain
stimulation for postural instability using tDCS stimulation
Objective of the study:
To test the efficacy of cerebellar transcranial direct current stimulation (tDCS) associated
with physical rehabilitation on postural instability and falls in progressive supranuclear
palsy using a double-blind design and wearing sensors technology
Design:
Twenty probable PSP patients with no dementia and still able to walk will be recruited for a
randomized double-blind sham-controlled study. Each patient will be hospitalized for a four
week physical rehabilitation. In the real-arm, the patients will undergo a 10 days cerebellar
tDCS stimulation while the placebo arm will undergo sham stimulation.
cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current
through a surface scalp electrode over the cerebellum for ten days.
Each patient will be evaluated before and after stimulation by berg balance tests (BBS),
Tinetti scale, PSP-rating scale (PSP-RS), cognitive assessment and a battery of gait and
movement tests using wearing sensors technology.
Sensors assessment:
The following parameters will be evaluated before and after stimulation (real vs sham): The
parameter for postural instability defined are:
i) TIME, defined as time without falling ii) The parameter "surface", defined as the sway
area iii) Velocity describes the mean velocity of the compensatory movements given in mm/s.
iv) Acceleration described as root mean square (RMS), v) Jerk, the time derivate of
acceleration, quantifies smoothness of the compensatory movements given in mG/s.
The parameter for gait and turning evaluation during normal walk and timed up and go, defined
are: i) stealth length ii) step variability iii) step phases duration iv) gait speed v)
turning velocity
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04096651 -
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Completed |
NCT00703677 -
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00382824 -
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
|
N/A | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04139551 -
Oxford Study of Quantification in Parkinsonism
|
||
Completed |
NCT02734485 -
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01110720 -
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
|
Phase 2/Phase 3 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
Completed |
NCT02460094 -
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
|
Phase 1 | |
Active, not recruiting |
NCT04993768 -
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
|
Phase 2 | |
Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
Completed |
NCT03058965 -
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
|
Early Phase 1 | |
Recruiting |
NCT02605785 -
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01353183 -
Analysis of the Enteric Nervous System Using Colonic Biopsies
|
N/A | |
Completed |
NCT00385710 -
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
|
Phase 2 | |
Recruiting |
NCT05260151 -
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
|